Skip to content

Levothyroxine Treatment for Critically Ill Adults with Non-Thyroidal Illness Syndrome

Levothyroxine Treatment for Critically Ill Adults with Non-Thyroidal Illness Syndrome: A Randomized Controlled Trial - LT4-NTIS RCT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129284
Enrollment
Unknown
Registered
2026-08-03
Start date
2023-06-13
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-thyroidal illness syndrome

Interventions

Control group:Conventional treatment
Levothyroxine treatment group:Conventional treatment combined with levothyroxine tablets

Sponsors

The First People's Hospital of Yunnan Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years and <=90 years; 2. Critically ill patients admitted to the ICU or MICU; 3. Diagnosis of non-thyroidal illness syndrome, defined as no history of primary thyroid or pituitary disease, decreased serum T3 or FT3, normal or decreased TSH, and normal or decreased T4 or FT4, with primary thyroid disease excluded according to clinical assessment; 4. Written informed consent provided by the patient or by the legally authorized representative/guardian.

Exclusion criteria

Exclusion criteria: 1. Age 90 years; 2. History of thyroid disease, including goiter; 3. Hypothalamic disease, pituitary disease, malignant tumor, or hematological disease; 4. Pregnant or perinatal women, or patients with psychiatric disorders; 5. Inability to receive enteral administration, including patients with acute gastrointestinal injury grade III or IV; 6. Acute myocardial infarction, acute myocarditis, acute pancarditis, severe arrhythmia, or acute heart failure at baseline; 7. Patients considered unsuitable for participation by the investigators.

Design outcomes

Primary

MeasureTime frame
Rate of organ function improvement;

Secondary

MeasureTime frame
28-day mortality;Serum TSH level;Serum T3 level;Serum T4 level;Serum FT3 level;Serum FT4 level;SOFA score;Levothyroxine-related adverse events;

Countries

China

Contacts

Public ContactChuming Fan

The First People's Hospital of Yunnan Province

fcming183@sina.com+86 871 6363 8569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026